Oncogene Eu is an innovative brand that offers personalized medical services in the field of oncology. Their mission is to support oncologists in making informed decisions for the selection of effective and safe treatment protocols for cancer patients. They achieve this through the evaluation of DNA, utilizing state-of-the-art genomic technologies like Next-Generation Sequencing (NGS).

With up-to-date data, Oncogene Eu provides personalized medical reports to oncologists, containing information about genetic mutations in tumors, treatment options, potential effectiveness and toxicity, as well as drug interactions. The accuracy and quality of their reports are ensured through the use of a registered medical device for diagnostic interpretation, MHGuide®. Patient data confidentiality and informed decision-making are also a priority for Oncogene Eu, ensuring that genetic information is used solely for the benefit of the tested individual.

With their personalized approach to cancer treatment, Oncogene Eu aims to contribute to the advancement of precision medicine